About Ovid Therapeutics Inc.

Ovid Therapeutics has maintained focused financial performance and market position in rare neurological diseases through strategic clinical development, efficient capital allocation, and innovative therapeutic advancement that addresses significant unmet medical needs in epilepsy and neurodevelopmental disorders where existing treatment options often provide inadequate seizure control or cause significant side effects. The company's financial discipline includes strategic clinical trial design, efficient resource utilization, and partnership development that support continued therapeutic advancement while managing development costs and extending financial runway in competitive rare disease markets. Through disciplined capital management and strategic development approaches, Ovid has built financial foundation that enables sustained clinical progress. OVID stock price performance often reflects investor assessment of the company's rare disease therapy potential and clinical development progress.

Ovid Therapeutics has developed comprehensive innovation and technology leadership through novel neurological therapeutic approaches, sophisticated drug development platforms, and advanced clinical development strategies that enable development of differentiated treatments for rare epilepsy conditions and neurodevelopmental disorders requiring improved therapeutic options. The company's technological capabilities include proprietary drug development approaches, innovative therapeutic mechanisms, and comprehensive clinical development expertise that support advancement of breakthrough neurological therapies through complex regulatory processes while maintaining safety and efficacy standards. Through continuous innovation in rare disease drug development, Ovid has established unique positioning in neurological treatment that differentiates from existing therapeutic approaches and competitive rare disease programs.

Ovid Therapeutics' growth strategy and future outlook emphasize clinical development excellence, regulatory advancement, and strategic partnerships that can drive successful therapeutic development while building market leadership in rare neurological diseases through continued innovation and clinical validation. The company's strategic initiatives focus on clinical execution, regulatory engagement, and partnership development that can accelerate therapeutic advancement while expanding commercial opportunities and market access for rare disease treatments. Management's commitment to rare neurological disease innovation, clinical excellence, and strategic development positions Ovid for advancement in neurology therapeutics through breakthrough treatment development and successful commercialization strategies that address critical rare disease needs requiring innovative neurological therapeutic approaches for improved patient outcomes.